Reviewing ALT5 Sigma (AIFC) and Its Competitors

ALT5 Sigma (NASDAQ:AIFC) is one of 343 publicly-traded companies in the “Financial Services” industry, but how does it compare to its rivals? We will compare ALT5 Sigma to related businesses based on the strength of its institutional ownership, analyst recommendations, risk, dividends, profitability, valuation and earnings.

Institutional and Insider Ownership

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 43.2% of shares of all “Financial Services” companies are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by insiders. Comparatively, 22.0% of shares of all “Financial Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for ALT5 Sigma and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1	0	0	0	1.00
ALT5 Sigma Competitors	1909	6749	11435	419	2.51

As a group, “Financial Services” companies have a potential upside of 3.24%. Given ALT5 Sigma’s rivals stronger consensus rating and higher possible upside, analysts clearly believe ALT5 Sigma has less favorable growth aspects than its rivals.

Profitability

This table compares ALT5 Sigma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-4,021.65%	-51.87%	-48.30%
ALT5 Sigma Competitors	-408.40%	-22.15%	-5.71%

Volatility & Risk

ALT5 Sigma has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Comparatively, ALT5 Sigma’s rivals have a beta of 2.27, meaning that their average share price is 127% more volatile than the S&P 500.

Earnings & Valuation

This table compares ALT5 Sigma and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ALT5 Sigma	$24.84 million	-$344.51 million	1.22
ALT5 Sigma Competitors	$6.31 billion	$1.08 billion	8.86

ALT5 Sigma’s rivals have higher revenue and earnings than ALT5 Sigma. ALT5 Sigma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

ALT5 Sigma rivals beat ALT5 Sigma on 13 of the 13 factors compared.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.